ENDOCYTE ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 VISION TRIAL OF 177LU-PSMA-617 IN PROSTATE CANCER
June 8, 2018
Endocyte, Inc. (Nasdaq:ECYT) announced the enrollment of the first patient in its global phase 3 VISION trial of 177Lu-PSMA-617 in prostate cancer by Dr. Luke Nordquist at Urology Cancer Center in Omaha, NE, a member of Precision Cancer Research.